Category: RESEARCH

Psychedelic Stock Review Initiates Coverage on Ehave Inc.

Psychedelic Stock Review Initiates Coverage on Ehave Inc. MIAMI, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics...

Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company

WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE What exactly is a favorite? First what it isn’t. In early August our research team...

Subscribe for Free!

EXCELLENT CHOICE, SIR! AND CHEERS TO YOU FOR SUBSCRIBING Subscribe For Your Free Copy to the 2021 Psychedelic Investor Guide

Cybin (CLXPF CYBN) Gets $8.00 Price Target From H.C. Wainwright.

Advancing Multiple Psychedelics in Multiple Indications; Initiating With a Buy and $8 Price Target. REPORT
Most Popular

‘Magic Mushroom’ Psychedelic may Help Heavy Drinkers Quit (AP News)

Psychedelic Drug Helped People with Alcohol use Disorder Reduce Drinking, Study Shows (Today) Psilocybin,...

Stan Grof, Psychedelic’s Elder Statesman.

Stan Grof — Lessons from ~4,500 LSD Sessions and Beyond https://youtu.be/3mdYUmvTeig PLAYLIST

PharmaTher (PHRM, PHRRF) $0.10 Gets $3.80 Price Target From H.C. Wainwright – 37 Times (3,700%) Higher.

Thus, to us, the key potential positive events that could lead to a rerating in PHRM.CN shares include publication of the Phase...